b65a6759-a9a4-4740-a9e3-962771dd9954
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ANGIOGENESIS+0.500
- COAGULATION+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.400
- TNFA_SIGNALING_VIA_NFKB+0.400
- APICAL_JUNCTION+0.300
- APOPTOSIS+0.300
- HEDGEHOG_SIGNALING+0.300
- HYPOXIA+0.300
- IL6_JAK_STAT3_SIGNALING+0.300
- KRAS_SIGNALING_UP+0.300
Top 10 suppressed
- E2F_TARGETS-0.700
- G2M_CHECKPOINT-0.600
- MITOTIC_SPINDLE-0.500
- MYC_TARGETS_V1-0.500
- MYC_TARGETS_V2-0.400
- MTORC1_SIGNALING-0.200
- OXIDATIVE_PHOSPHORYLATION-0.200
- PROTEIN_SECRETION-0.200
- UNFOLDED_PROTEIN_RESPONSE-0.200
- DNA_REPAIR-0.100
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | 45b4921e-fce7-41f8-bb63-ed98343ceec8 | — | — | 0.923 |
| 2 | SRR8392884 | — | cohortA1 | 0.905 |
| 3 | R89 | — | — | 0.896 |
| 4 | MDT-AP-0384 | Med | Medulloblastoma | 0.892 |
| 5 | SRR25043631 | — | — | 0.884 |
| 6 | 88322 | EPN | Supratentorial EPN | 0.883 |
| 7 | SAMN03290935 | — | — | 0.879 |
| 8 | TCGA-E2-A153-01A-12R-A12D-07 | — | A | 0.877 |
| 9 | SRR1341702 | GTEX | — | 0.875 |
| 10 | SRR12475155 | — | — | 0.874 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ANGIOGENESIS | 0.500 | Remibrutinib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.400 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.400 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.300 | Inavolisib | — uncovered |
| APOPTOSIS | 0.300 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.300 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.300 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.300 | Inavolisib | — uncovered |
| MYOGENESIS | 0.300 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.300 | Idelalisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.300 | Cobimetinib | — uncovered |
| TGF_BETA_SIGNALING | 0.300 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.200 | Temsirolimus | — uncovered |
| COMPLEMENT | 0.200 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.200 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.200 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.200 | Remibrutinib | — uncovered |